Cargando…

Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model

The small-molecule antiviral drug ensitrelvir targets the 3C-like protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study evaluated its inhibitory effect on viral replication in a delayed-treatment mouse model and investigated the relationship between pharmacokinetic (PK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukao, Keita, Nobori, Haruaki, Kuroda, Takayuki, Baba, Kaoru, Matsumoto, Kazumi, Tanaka, Yukari, Tachibana, Yuki, Kato, Teruhisa, Shishido, Takao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612060/ https://www.ncbi.nlm.nih.gov/pubmed/37896829 http://dx.doi.org/10.3390/v15102052

Ejemplares similares

Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally
por: Kawashima, Sho, et al.
Publicado: (2023)

Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
por: Ip, Jonathan Daniel, et al.
Publicado: (2023)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses
por: Kuroda, Takayuki, et al.
Publicado: (2023)

Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection
por: Fukao, Keita, et al.
Publicado: (2019)

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
por: Unoh, Yuto, et al.
Publicado: (2022)

S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters
por: Sasaki, Michihito, et al.
Publicado: (2022)

Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants
por: Lin, Mengmeng, et al.
Publicado: (2023)

530. Population Pharmacokinetic Analysis of Ensitrelvir, an Inhibitor of 3C-like (3CL) Protease of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) for patients with SARS-Cov-2 Infection
por: Ishibashi, Toru, et al.
Publicado: (2023)

1343. Prophylactic Dosing of Baloxavir Acid Eliminates Mortality in Mice Lethal Influenza A Virus Infection Model
por: Shano, Shinya, et al.
Publicado: (2018)

Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
por: Noske, Gabriela Dias, et al.
Publicado: (2023)

Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
por: Fukao, Keita, et al.
Publicado: (2023)

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations
por: Shimizu, Ryosuke, et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Development of a Manufacturing Process toward the Convergent Synthesis of the COVID-19 Antiviral Ensitrelvir
por: Kawajiri, Takahiro, et al.
Publicado: (2023)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
por: Mukae, Hiroshi, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
por: Taniguchi, Keiichi, et al.
Publicado: (2022)

Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma
por: Jung, Seowoong, et al.
Publicado: (2023)

Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil
por: Taniguchi, Keiichi, et al.
Publicado: (2019)

548. Combined Results of the Phase 2a/2b/3 Randomized Controlled Trials of Ensitrelvir for the Treatment of COVID-19 Infection
por: Tsuge, Yuko, et al.
Publicado: (2023)

Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
por: Katsube, Takayuki, et al.
Publicado: (2019)

Recent Advances in Translational Pharmacokinetics and Pharmacodynamics Prediction of Therapeutic Antibodies Using Modeling and Simulation
por: Haraya, Kenta, et al.
Publicado: (2022)

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections
por: Matsumoto, Kazuaki, et al.
Publicado: (2016)

The Pharmacokinetics and Pharmacodynamics of Iron Preparations
por: Geisser, Peter, et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide
por: Chen, Nianhang, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Micafungin
por: Wasmann, Roeland E., et al.
Publicado: (2017)

Clinical Pharmacokinetics and Pharmacodynamics of Propofol
por: Sahinovic, Marko M., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
por: Black, Donald M., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine
por: Weerink, Maud A. S., et al.
Publicado: (2017)

Deciphering pharmacokinetics and pharmacodynamics of fosfomycin
por: Rodríguez-Gascón, Alicia, et al.
Publicado: (2019)

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0q0ng4dd6i9svsgm1gmndmv9ao